Cyclosporine protects glomeruli from FSGS factor via an increase in glomerular cAMP

Transplantation

Volumn 62, Issue 12, 1996, Pages 1916-1920

  Sharma, Ram ^a   Sharma, Mukut ^a   Ge, Xiuli ^a   Mccarthy, Ellen T ^a   Savin, Virginia J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

ALBUMINS; ANIMALS; CYCLIC AMP; CYCLOSPORINE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLYCEROL; HUMANS; KIDNEY GLOMERULUS; MALE; MICROSCOPY, ELECTRON; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE;

EID: 0030444715     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199612270-00041     Document Type: Conference Paper

References (40)

1. Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerular sclerosis in children. Pediatr Nephrol 1991; 5: 393.
2. Senguttuvan P, Cameron JS, Hartley RB, et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factor in 59 allografts. Pediatr Nephrol 1990; 4: 21.
3. Laufer J, Ettenger RB, Hot WG, Cohen AH, Marik JL, Fine RN. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation 1988; 46: 540.
4. Artero M, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injury glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994; 23: 574.
5. Dantal J, Bigot E, Boger SW, et al. Effect of plasma protein absorption on protein excretion in kidney transplant recipient with recurrent nephrotic syndrome. N Engl J Med 1994; 330: 7.
6. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996; 334: 878.
7. Sharma M, Ge X, Sharma R, McCarthy ET, Savin VJ. Partial purification of protein permeability factor from focal segmental glomerulosclerosis (FSGS) sera. JASN 1995; 6: 884.
8. Kooijmans-coutinho MF, Tegzess AM, Bruijn JA, Florijn KW, van Es LA. Indomethacin treatment of recurrent nephrotic syndrome and focal segmental glomerulosclerosis after renal transplantation. Nephrol Dial Transplant 1993; 8: 469.
9. Velosa JA, Torres VE, Donadio JV, Wagoner RD, Holley KE, Offord KP. Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study. Mayo Clin Proc 1985; 60: 586.
10. Heeg JE, de Jong PE, van der Hem GK. Efficacy and variability of the anti-proteinuric effect of ACE-inhibition by lisinopril. Kidney Int 1989; 36: 272.
11. Heeg JE, de Jong PE, Vriesendorp R, de Zeeuw D. Anti-proteinuric effect of the NSAID indomethacin and the ACE-inhibitor lisinopril. Am J Nephrol 1990; 10: 94.
12. Ingulli E, Tejani A, Khalid MHB, et al. High dose cyclosporin therapy in recurrent nephrotic syndrome following renal transplantation. Transplantation 1990; 49: 219.
13. Artero M, Biava C, Amend W, Tomlanovic S, Vincenti F. Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med 1992; 92: 375.
14. Zietse R, Wenting GJ, Kramer P, Mulder P, Schalekamp MA, Weimer W. Contrasting response to cyclosporin in refractory nephrotic syndrome. Clin Nephrol 1989; 31: 22.
15. Tejani A, Ingulli E. Current concepts of pathogenesis of nephrotic syndrome. Contrib Nephrol 1995; 114: 1.
16. Zietse R, Derkx FHM, Schalekamp MADH, Weimer W. Cyclosporin and the glomerular filtration barrier in minimal change disease and membranous glomerulopathy. Contrib Nephrol 1995; 114: 6.
17. Sharma R, Savin VJ. Cyclosporine prevents the increase in glomerular albumin permeability caused by serum from patients with focal segmental glomerular sclerosis. Transplantation 1996; 61: 381.
18. Wiegmann TB, Sharma R, Diederich DA, Savin VJ. In vitro effects of cyclosporine on glomerular function. Am J Med Sci 1990; 299: 149.
19. Sharma R, Wiegmann TB, Savin VJ. Vasoactive substances induce cytoskeletal changes in cultured rat glomerular epithelial cells. J Am Soc Nephrol 1992; 3: 1131.
20. Pinnick RV, Savin VJ. Filtration by superficial and deep glomeruli of normovolemic and volume depleted rats. Am J Physiol 1986; 250: 19 F86.
21. Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient using isolated rat glomeruli. J Am Soc Nephrol 1992; 3: 1260.
22. Daniel BS. The role of the glomerular epithelial cells in the maintenance of the glomerular filtration barrier. Am J Nephrol 1993; 13: 318.
23. Savin VJ. Mechanisms of proteinuria in non inflammatory glomerular diseases. Am J Kidney Dis 1993; 21: 347.
24. Savin VJ, Johnson R, Couser WG. C5b-9 increases albumin permeability of isolated glomeruli in vitro. Kidney Int 1994; 46: 382.
25. Dileepan KN, Sharma R, Stechschulte DJ, Savin VJ. Effect of superoxide exposure on albumin permeability of isolated rat glomeruli. J Lab Clin Med 1993; 121: 797.
26. Li JZ, Sharma R, Dileepan KN, Savin VJ. Polymorphonuclear leukocytes increase albumin permeability via hypohalous acid. Kidney Int 1994; 46: 1025.
27. albumin) in rat glomeruli induced by sera of children with native and recurrent focal segmental glomerulosclerosis (FSGS): implications in renal transplantation. JASN 1994; 5: 1026.
28. Alavi N, Lianos EA, Venuto RC, et al. Reduction of proteinuria by indomethacin in patients with nephrotic syndrome. Am J Kidney Dis 1986; 8: 397.
29. Laurent J, Belghiti D, Bruneau C, et al. Diclofenac, a nonsteroidal antiinflammatory drug, decreases proteinuria in some glomerular diseases. Am J Nephrol 1987; 7: 198.
30. Donker AJM, Brentjens JRH, Van der Hen GK, et al. Treatment of the nephrotic syndrome with indomethacin. Nephron 1987; 22: 374.
31. Golbetz H, Black V, Shemesh O, et al. Mechanism of the anti-proteinuric effect of Indomethacin in nephrotic humans. Am J Physiol 1989; 256: F44.
32. Myer LH, Schrier RW. Cyclosporin A enhances vasopressin-induced calcium mobilization and contraction in mesangial cells. Kidney Int 1988; 34: 89.
33. Sigal NH, Dumont F, Durette P, et al. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Lab Clin Med 1991; 173: 619.
34. 2+ poisoning mitochondria: in vivo and in vitro studies. Comp Biochem Physiol Pharmacol Toxicol Endocrinol 1994; 107: 429.
35. Bunchman TE, Brookshire CA. Cyclosporin-induced synthesis ot endothelin by cultured human endothelial cells. J Clin Invest 1991; 88: 310.
36. Roger PP, Rickaert F, Huez G, Authelet M, Hoffman F, Dumont JE. Microinjection of catalytic subunit of cyclic AMP-dependent protein kinases triggers acute morphological changes in thyroid epithelial cells. FEBS Lett 1988; 232: 409:
37. Chaldakov GN, Nabika T, Nara Y, Yamori Y. Cyclic AMP and cytochalasin B-induced arborization in cultured smooth muscle cells: its cytopharmacological characterization. Cell Tissue Res 1989; 255: 435.
38. Mangoo-Karim R, Uchic ME, Grant M, et al. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB J 1989; 3: 2629.
39. Mills JW, Lubin M. Effect of adenosine 3′,5′-cyclic monophosphate on volume and cytoskeleton of MDCK cells. Am J Physiol 1986; 250: C319.
40. Drenckhahn D, Franke RP. Ultrastructural organization of contractile and cytoskeletal proteins in glomerular podocytes of chicken, rat, and man. Lab Invest 1988; 59: 673.